Catalog No.
Product Name
Application
Product Information
Citations
- Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity.
- Sochaj-Gregorczyk AM, .et al. , J Immunother, 2016, Jul-Aug;39(6):223-32 PMID: 27227324
- Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A.
- alpha-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting RNA-polymerase II.
- Aldoxorubicin (INNO-206) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
- Duocarmycin is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity. Duocarmycin is a DNA minor groove binding alkylating agent and explored as drug?Cantibody conjugates (ADCs) .
-
DNA alkylating agent
(+)-CBI-CDPI2 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI2 is an antibody drug conjugates (ADCs) toxin. -
DNA alkylating agent
(+)-CBI-CDPI1 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI1 is an antibody drug conjugates (ADCs) toxin. -
DNA alkylating agent
Duocarmycin GA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-drug resistant cell lines. -
ADCs toxin
Duocarmycin MB is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MB can be used against multi-drug resistant cell lines. - 10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features.
-
antibody drug conjugates (ADCs) toxin
Duocarmycin MA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MA can be used against multi-drug resistant cell lines. -
microtubulin inhibitor
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. - Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.
-
tubulin inhibitor
altobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin. -
cytotoxic tubulin modifier
Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates. Auristatin F inhibits cell division by blocking the polymerisation of tubulin. -
cytotoxic tubulin modifier
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin. - Dolastatin 10 (DLS 10) is a potent antimitotic peptide, isolated from the marine mollusk Dolabela auricularia, that inhibits tubulin polymerization.
-
ADCs cytotoxin
PNU-159682, a highly potent metabolite of the anthracycline nemorubicin (DNA topoisomerase II inhibitor) with outstanding cytotoxicity, is a potent ADCs cytotoxin. -
ADC Cytotoxin
Mytoxin B is an ADC cytotoxin that functions as a satratoxin-type trichothecene macrolide. It is known for inducing cell apoptosis primarily through the PI3K/Akt signaling pathway. This compound is utilized in research applications focused on targeted cancer therapies and the study of apoptosis mechanisms in various cell types. -
ADC Cytotoxin
γ-Amanitin is a potent ADC cytotoxin derived from the Amanita mushroom, specifically targeting RNA polymerase II to inhibit mRNA synthesis. This compound exhibits high toxicity across various cell types, making it a valuable tool in cancer research and therapeutic applications. γ-Amanitin competes effectively with monoclonal antibodies, displaying an IC50 value of 163.1 ng/mL. Its ability to disrupt transcriptional processes positions it as a key reagent in studies focused on gene expression and cellular response mechanisms. -
ADC Payload
Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid is a cytotoxic pyrrolobenzodiazepine (PBD) dimer derivative designed for use as an antibody-drug conjugate (ADC) payload. This compound exhibits moderate DNA alkylating activity, contributing to its potent cytotoxic effects on target cells. It is primarily utilized in research applications focused on developing targeted cancer therapies through antigen-dependent cytotoxicity mechanisms. -
ADC Payload
(S,S)-D211 is a stereoisomer of D211 that functions as a potent ADC payload through its DNA-damaging activity. As a member of the PBD dimer family, (S,S)-D211 is designed for incorporation into antibody-drug conjugates (ADCs), enhancing their cytotoxic efficacy in targeted cancer therapies. Its ability to induce DNA damage makes it a valuable tool for research in the development of innovative cancer treatments. -
ADC Cytotoxin
Exatecan Intermediate 2 is an important precursor in the synthesis of Exatecan, a camptothecin analog with potent anticancer properties. This compound targets DNA, disrupting the proliferation and division of tumor cells, thereby inhibiting tumor growth. It is primarily employed in research focused on various cancers, including ovarian, lung, and breast cancers, making it a valuable tool in oncology studies. -
ADC Cytotoxin
Cyclopropaneacetamide-Exatecan is an analogue of Exatecan, functioning as an ADC (antibody-drug conjugate) cytotoxin. Its primary mechanism involves targeting cancer cells to deliver cytotoxic agents selectively, enabling effective tumor treatment. This compound is instrumental in the synthesis of ADC molecules and is valuable for research applications focused on cancer therapeutics and drug delivery systems. -
ADC Cytotoxin
7-MAD-MDCPT is a potent Camptothecin analog designed as a cytotoxic agent in antibody-drug conjugates (ADCs). Its primary mechanism involves the inhibition of topoisomerase I, leading to DNA damage and subsequent apoptosis in proliferating cells. This compound is utilized in the development of targeted cancer therapies, enhancing the effectiveness and specificity of ADCs in oncology research. -
ADC Cytotoxin
PBD-monoamide, a modified pyrrolobenzodiazepine (PBD) dimer, serves as an antibody-drug conjugate (ADC) cytotoxin. This compound exhibits DNA-binding activity, leading to reduced cell viability, making it a valuable tool for cancer research. PBD-monoamide is utilized in the synthesis of DHES0815A, an ADC targeting HER2, facilitating the study of targeted cancer therapies. -
ADC Cytotoxin/TopI Inhibitor
ZD06519 is a potent ADC cytotoxin and a topoisomerase I inhibitor derived from camptothecin. It exhibits a significant bystander effect, effectively inhibiting various malignancies, including HER2-positive and FRα-overexpressing tumors. By interfering with DNA cleavage, relaxation, and reconnection, ZD06519 induces apoptosis in tumor cells. This compound is ideal for ADC synthesis and applications in cancer research. -
ADC cytotoxin
NMT-IN-7 is a potent inhibitor of N-myristoyl transferase (NMT), exhibiting IC50 values of 2.1 nM for HsNMT1M and 0.6 nM for SU-DHL-10 cells. This compound functions effectively as an antibody-drug conjugate (ADC) cytotoxin, demonstrating significant potential in targeted cancer therapy. Its selective inhibition of NMT may facilitate the study of myristoylation in biological processes and contribute to the development of novel therapeutic strategies. -
ADC Cytotoxin
Fmoc-MMAE is a protective group-conjugated derivative of monomethyl auristatin E (MMAE), functioning primarily as a tubulin inhibitor. This compound exhibits potent cytotoxicity, making it valuable in the design and development of antibody-drug conjugates (ADCs). Its application in ADC synthesis allows for targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. -
ADC Payload
(R)-Benzyl 2-cyclopropyl-2-hydroxyacetate is an ADC payload precursor, designed to facilitate the synthesis of pyrrolidines. This compound plays a crucial role in constructing targeted antibody-drug conjugates, enhancing the specificity and efficacy of therapeutic agents in cancer research. Researchers utilizing this reagent can explore advanced applications in drug development and improve therapeutic strategies. -
ADC Cytotoxin
N-Me-L-Ala-maytansinol is an ADC cytotoxin that serves as a potent cell-permeable payload for antibody-drug conjugates. It exhibits significant cytotoxic activity against target cells, making it a valuable reagent in cancer therapeutics research. This compound is instrumental in the development of targeted therapies by enhancing the selectivity and efficacy of ADCs in preclinical studies. -
ADC Cytotoxin
SC209, a 3-aminophenyl hemiasterlin derivative, targets tubulin as an ADC cytotoxin. This compound demonstrates reduced efflux potential through the P-glycoprotein 1 pump when compared to other tubulin-targeting agents, enhancing its efficacy in therapeutic applications. SC209 exhibits significant antitumor activity and is suitable for the synthesis of antibody-drug conjugates (ADCs), making it a valuable reagent in cancer research. -
ADC Cytotoxin
Duostatin 5 is an ADC cytotoxin that serves as a synthetic building block for antibody-drug conjugates (ADCs). It is derived from MMAF and allows for efficient conjugation to antibodies targeting 5T4 through a disubstituted C-Lock linker, enabling stable and straightforward synthesis. Duostatin 5 features an azide functional group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO or BCN groups. This reagent is valuable for researchers developing targeted therapies in cancer treatment. -
ADC Cytotoxin
Maytansinoid B is an ADC cytotoxin that specifically targets tubulin, acting as an antimitotic agent by inhibiting microtubule assembly. This compound can be conjugated with antibodies to form effective antibody-drug conjugates (ADCs), facilitating targeted cancer therapies. By inducing G2/M cell cycle arrest, Maytansinoid B promotes apoptosis in rapidly dividing cells, making it a valuable tool for cancer research and therapeutic applications. -
ADC Cytotoxin
N-Ac-γ-Calicheamicin-AcBut-NHS ester is an ADC cytotoxin that induces cell cycle arrest and apoptosis through the formation of DNA double-strand breaks. This compound is primarily utilized in the synthesis of antibody-drug conjugates (ADCs) and is particularly relevant in cancer research, including studies related to acute lymphoblastic leukemia (ALL) and various hematological malignancies. Its potent cytotoxic properties make it a valuable tool for advancing therapeutic strategies in oncology. -
ADC Cytotoxin
Hydrotecan is a derivative of Camptothecin, specifically designed as an antibody-drug conjugate (ADC) cytotoxin. It exhibits potent antitumor activity by inducing apoptosis in cancer cells through its action on topoisomerase I. This compound is valuable for the synthesis of ADC molecules, facilitating targeted cancer therapy research and development. -
ADC Cytotoxin
DC0-NH2 is an effector moiety targeting antibody-drug conjugates (ADCs) with enhanced stability compared to its analog DC1. This compound exhibits remarkable cytotoxicity, demonstrating approximately 1000-fold greater potency than traditional anticancer agents like Doxorubicin. The mechanism involves binding to the minor groove of DNA, leading to alkylation of adenine residues via its propabenzindole (CBI) moiety, making it a valuable candidate for cancer research and therapeutic applications. -
ADC Cytotoxin
DM3, a Maytansine analog, is a potent tubulin inhibitor that contains disulfide or thiol groups. As a key cytotoxic component of antibody-drug conjugates (ADCs), DM3 is designed to selectively target and eliminate cancer cells. Its ability to disrupt microtubule formation makes it valuable in cancer research and the development of targeted therapies. -
ADC Cytotoxin
7-MAD-MDCPT hydrochloride is a Camptothecin analog that serves as a cytotoxic payload in antibody-drug conjugates (ADCs). This compound demonstrates potent anti-cancer activity by targeting topoisomerase I, leading to DNA damage and subsequent apoptosis in cancer cells. It is primarily utilized in research focused on developing targeted cancer therapies and enhancing the efficacy of ADCs. -
ADC Cytotoxin
7-Aminomethyl-10-methyl-11-fluoro camptothecin is a potent cytotoxin targeting cancer cells through its mechanism of acting as a topoisomerase inhibitor. This compound serves as an essential intermediate for the synthesis of camptothecin-based antibody-drug conjugates (ADCs), which are designed to deliver targeted therapeutic agents to tumor cells. Its applications in cancer research support the development of innovative treatments aimed at improving the efficacy of chemotherapy while reducing systemic toxicity. -
ADC Cytotoxin
Tomaymycin DM is a derivative of tomaymycin that acts as a DNA alkylating agent, functioning primarily as a payload in antibody-drug conjugates (ADCs). This compound exhibits potent cytotoxic activity, targeting tumor cells through selective delivery mechanisms associated with ADCs. Tomaymycin DM is essential for research into targeted cancer therapies and the development of novel ADC formulations. -
ADC Cytotoxin
Exatecan Intermediate 2 hydrochloride is a cytotoxic agent targeting DNA through its mechanism as a camptothecin analog. This compound plays a critical role in the synthesis of Exatecan, an anticancer agent known for its efficacy against various malignancies, including ovarian, lung, and breast cancers. Exatecan Intermediate 2 hydrochloride is primarily utilized in research focused on cancer biology and therapeutic development. -
ADC Cytotoxin
Exatecan Intermediate 4, a key intermediate in the synthesis of Exatecan (DX-8951), functions as an ADC cytotoxin. This compound exhibits potent antitumor activity by disrupting DNA replication, leading to the inhibition of cancer cell proliferation. It is utilized in research related to various malignancies, including ovarian, lung, and breast cancers, providing insights into targeted cancer therapies and drug development. -
ADC Cytotoxin
PNU-159682 carboxylic acid is a potent cytotoxin utilized in antibody-drug conjugates (ADCs) targeting the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. This compound exhibits diverse biological activities, including modulation of cell adhesion, cell-cell signaling, and glycoprotein turnover. It plays significant roles in inflammation and immune response, making it valuable for research applications in oncology and immunology.
